Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldi, Federico, Dentone, Chiara, Mikulska, Malgorzata, Fenoglio, Daniela, Mirabella, Michele, Magnè, Federica, Portunato, Federica, Altosole, Tiziana, Sepulcri, Chiara, Giacobbe, Daniele Roberto, Uras, Chiara, Scavone, Graziana, Taramasso, Lucia, Orsi, Andrea, Cittadini, Giuseppe, Filaci, Gilberto, Bassetti, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868302/
https://www.ncbi.nlm.nih.gov/pubmed/36698815
http://dx.doi.org/10.3389/fmed.2022.1062450
Descripción
Sumario:COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replication and disease progression. We report the cases of two patients, both treated with rituximab for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, and both hospitalized for COVID-19 with positive SARS-CoV-2 RNAemia, who were successfully treated with a salvage combination therapy with sotrovimab, remdesivir and nirmatrelvir/ritonavir.

Ejemplares similares